Europe — EMA

Ocrevus (Ocrelizumab)

Ocrelizumab, the active ingredient in Ocrevus, is a monoclonant presented as a / for intravenous use. It treats multiple sclerosis in adult patients.

Ocrelizumab

Request sourcing

Pack/s

What is Ocrelizumab?

Ocrelizumab, the active ingredient in Ocrevus, is a monoclonant presented as a / for intravenous use. It treats multiple sclerosis in adult patients. GNH USA supplies Ocrevus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

GNH USA supplies Ocrevus as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals worldwide.

What is Ocrelizumab used for?

Ocrevus is a monoclonal antibody that targets - Relapsing‑remitting multiple sclerosis: reduces the ... - .... - ...

What are the side effects of Ocrelizumab?

Common - - ...

Frequently asked questions

What … +

…

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →